UroGen Pharma Ltd. (URGN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
36/54
3.3 / 5 stars
All 54 Win/Lose results and 66 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 7 wins, 1 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinURGN / S&P 104.67% / 15.20% |
WinURGN / S&P 100.27% / 15.00% |
No dataURGN / S&P / 50.40% |
| 2026-Q11/2 |
LoseURGN / S&P -23.23% / -4.33% |
WinURGN / S&P 52.92% / 11.30% |
No dataURGN / S&P / 27.70% |
| 2025-Q42/2 |
WinURGN / S&P 17.39% / 2.65% |
WinURGN / S&P 21.45% / 9.00% |
No dataURGN / S&P / 13.40% |
| 2025-Q32/2 |
WinURGN / S&P 45.62% / 8.12% |
WinURGN / S&P 8.00% / 4.61% |
No dataURGN / S&P / 13.45% |
| 2025-Q22/2 |
WinURGN / S&P 23.87% / 10.94% |
WinURGN / S&P 10.85% / 4.83% |
No dataURGN / S&P / 10.63% |
| 2025-Q12/2 |
WinURGN / S&P 3.85% / -4.27% |
WinURGN / S&P 8.98% / 4.98% |
No dataURGN / S&P / 10.57% |
| 2024-Q41/2 |
LoseURGN / S&P -16.14% / 2.41% |
WinURGN / S&P 9.29% / 5.25% |
No dataURGN / S&P / 6.15% |
| 2024-Q31/2 |
LoseURGN / S&P -24.31% / 5.89% |
WinURGN / S&P 15.64% / 5.89% |
No dataURGN / S&P / 6.11% |
| 2024-Q22/2 |
WinURGN / S&P 11.87% / 4.28% |
WinURGN / S&P 17.22% / 5.38% |
No dataURGN / S&P / 5.12% |
| 2024-Q11/2 |
LoseURGN / S&P 0.00% / 10.56% |
WinURGN / S&P 24.00% / 5.71% |
No dataURGN / S&P / 5.59% |
| 2023-Q41/2 |
LoseURGN / S&P 7.07% / 11.69% |
WinURGN / S&P 28.52% / 6.81% |
No dataURGN / S&P / 7.78% |
| 2023-Q32/2 |
WinURGN / S&P 35.36% / -3.27% |
WinURGN / S&P 23.76% / 7.52% |
No dataURGN / S&P / -5.03% |
| 2023-Q22/2 |
WinURGN / S&P 12.01% / 8.74% |
WinURGN / S&P 25.70% / 9.50% |
No dataURGN / S&P / -8.57% |
| 2023-Q11/2 |
LoseURGN / S&P 4.17% / 7.50% |
WinURGN / S&P 25.62% / 10.77% |
No dataURGN / S&P / -15.69% |
| 2022-Q41/2 |
LoseURGN / S&P 6.61% / 7.56% |
WinURGN / S&P 33.96% / 11.88% |
No dataURGN / S&P / -17.99% |
| 2022-Q32/2 |
WinURGN / S&P 1.59% / -4.88% |
WinURGN / S&P 56.75% / 13.47% |
No dataURGN / S&P / -1.41% |
| 2022-Q22/2 |
WinURGN / S&P -5.97% / -16.10% |
WinURGN / S&P 80.61% / 13.71% |
No dataURGN / S&P / 11.04% |
| 2022-Q11/2 |
LoseURGN / S&P -8.41% / -4.60% |
WinURGN / S&P 180.65% / 15.97% |
No dataURGN / S&P / 42.23% |
| 2021-Q40/1 |
LoseURGN / S&P -43.46% / 11.03% |
No dataURGN / S&P / 15.00% |
No dataURGN / S&P / 96.40% |
| 2021-Q31/1 |
WinURGN / S&P 10.15% / 0.58% |
No dataURGN / S&P / 10.77% |
No dataURGN / S&P / 69.42% |
| 2021-Q20/1 |
LoseURGN / S&P -21.61% / 8.55% |
No dataURGN / S&P / 6.58% |
No dataURGN / S&P / 51.81% |
| 2021-Q11/1 |
WinURGN / S&P 8.10% / 6.17% |
No dataURGN / S&P / -1.06% |
No dataURGN / S&P / 7.39% |
| 2020-Q40/1 |
LoseURGN / S&P -6.58% / 12.15% |
No dataURGN / S&P / -3.72% |
No dataURGN / S&P / -33.42% |
| 2020-Q30/1 |
LoseURGN / S&P -26.15% / 8.93% |
No dataURGN / S&P / -2.04% |
No dataURGN / S&P / -27.10% |
| 2020-Q21/1 |
WinURGN / S&P 46.41% / 20.54% |
No dataURGN / S&P / -0.46% |
No dataURGN / S&P / -27.11% |
| 2020-Q10/1 |
LoseURGN / S&P -46.54% / -19.60% |
No dataURGN / S&P / 3.47% |
No dataURGN / S&P / -14.75% |
| 2019-Q41/1 |
WinURGN / S&P 40.03% / 9.07% |
No dataURGN / S&P / 5.36% |
No dataURGN / S&P / 2.99% |
| 2019-Q30/1 |
LoseURGN / S&P -33.70% / 1.70% |
No dataURGN / S&P / 5.02% |
No dataURGN / S&P / 0.21% |
| 2019-Q20/1 |
LoseURGN / S&P -2.71% / 4.30% |
No dataURGN / S&P / 6.64% |
No dataURGN / S&P / 8.65% |
| 2019-Q10/1 |
LoseURGN / S&P -14.21% / 13.65% |
No dataURGN / S&P / 8.12% |
No dataURGN / S&P / 14.29% |
| 2018-Q41/1 |
WinURGN / S&P -8.83% / -13.52% |
No dataURGN / S&P / 9.05% |
No dataURGN / S&P / 18.23% |
| 2018-Q30/1 |
LoseURGN / S&P -5.08% / 7.71% |
No dataURGN / S&P / 10.21% |
No dataURGN / S&P / 19.06% |
| 2018-Q20/1 |
LoseURGN / S&P 0.14% / 3.43% |
No dataURGN / S&P / 9.03% |
No dataURGN / S&P / 14.46% |
| 2018-Q11/1 |
WinURGN / S&P 33.54% / -0.76% |
No dataURGN / S&P / 7.68% |
No dataURGN / S&P / 12.46% |
| 2017-Q41/1 |
WinURGN / S&P 18.05% / 6.64% |
No dataURGN / S&P / 7.03% |
No dataURGN / S&P / 13.82% |
| 2017-Q31/1 |
WinURGN / S&P 74.53% / 4.48% |
No dataURGN / S&P / 5.68% |
No dataURGN / S&P / 17.57% |
| 2017-Q20/0 |
No dataURGN / S&P / 3.09% |
No dataURGN / S&P / 4.83% |
No dataURGN / S&P / 17.74% |
| 2017-Q10/0 |
No dataURGN / S&P / 6.07% |
No dataURGN / S&P / 3.67% |
No dataURGN / S&P / 13.32% |
| 2016-Q40/0 |
No dataURGN / S&P / 3.82% |
No dataURGN / S&P / 2.09% |
No dataURGN / S&P / 7.05% |
| 2016-Q30/0 |
No dataURGN / S&P / 3.85% |
No dataURGN / S&P / 0.20% |
No dataURGN / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | URGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 133.93% | 20.78% |
| Annualized return | 133.93% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | URGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 151.24% | 83.14% |
| Annualized return | 20.23% | 12.86% |
10Y · 2017-05-04 to 2026-08-27
| Metric | URGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 225.46% | 319.30% |
| Annualized return | 12.53% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |